CSTL Q4 2023 Earnings — Castle Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CSTLCastle Biosciences, Inc.

$805M

Q4 2023 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$66M+72.5% YoY

Gross Profit

$54M81.2% margin

Operating Income

-$6M-8.6% margin

Net Income

-$3M-3.9% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

+7.5%

Cash Flow

Operating Cash Flow

$19M

Free Cash Flow

$15M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$453M

Total Liabilities

$62M

Stockholders' Equity

$391M

Cash & Equivalents

$99M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$66M	$38M	+72.5%
Gross Profit	$54M	$29M	+86.3%
Operating Income	-$6M	-$23M	+75.2%
Net Income	-$3M	-$21M	+87.5%

Revenue Segments

Dermatologic

$53M100%